AXGN: Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for AXGN
Across the 6 sessions after earlier AXGN headlines, the stock closed higher 4 times and lower 2 times, with a median move of 6.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AXGN | SPY |
|---|---|---|---|
| Jan 12, 2026 | Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 | -5.8% | +0.2% |
| Dec 17, 2025 | Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference | +7.0% | -1.1% |
| Dec 4, 2025 | Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) | +16.0% | +0.1% |
| Dec 1, 2025 | Mizuho initiated coverage on AxoGen with a new price target | -0.4% | -0.5% |
| Nov 4, 2025 | Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences | +2.2% | -1.2% |
| Oct 29, 2025 | Axogen, Inc. Reports Third Quarter 2025 Financial Results | +23.1% | +0.0% |
Quantisnow market dataNASDAQ
AXGN
Axogen Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
Get push alerts for AXGN
Full AXGN profile on Quantisnow Follow AXGN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time